{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:06:48Z","timestamp":1790089608731,"version":"4.0.1"},"reference-count":43,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Double-hit lymphoma (DHL) and triple-hit lymphoma (THL) are aggressive subtypes of high-grade B-cell lymphoma with poor prognosis. This study evaluated the efficacy and safety of selinexor, a first-in-class oral inhibitor of exportin 1 (XPO1), combined with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; S-RCHOP) as first-line therapy for DHL\/THL. This single-arm, prospective phase 2 study enrolled 13 patients from May 2022 to August 2024. Patients received up to 6 21-day cycles of S-RCHOP (selinexor 60 mg on days 1, 8, 15). The primary end point was overall response rate (ORR). Secondary end points included progression-free survival (PFS), overall survival (OS), central nervous system (CNS) relapse rate within 2 years, and adverse events (AEs). Exploratory analyses included next-generation sequencing (NGS) and circulating cell-free DNA (cfDNA) monitoring. Thirteen patients (9 DHL and 4 THL) were enrolled. ORR was 100% (complete response [CR], 76.9%; partial response, 23.1%). At a median follow-up of 25.4 months, the 2-year PFS and OS were 67.7% and 67.1%, respectively. One patient developed CNS relapse. The most common all-grade AEs included leukopenia and neutropenia (55.1% each), febrile neutropenia and fatigue (43.5% each), and thrombocytopenia (33.7%). NGS and cfDNA revealed frequent BCL6 and IGLL5 mutations. Posttreatment cfDNA negativity was achieved in 72.7% of patients, all of whom were in CR by positron emission tomography\u2013computed tomography. In this study, S-RCHOP achieved high response rates in DHL\/THL but was associated with frequent hematologic AEs. cfDNA monitoring provided valuable insights into treatment response. These preliminary findings support further investigation of XPO1 inhibition combined with R-CHOP, with priority given to dose optimization. This trial was registered at www.clinicaltrials.gov as NCT05974085.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018580","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:00:46Z","timestamp":1784671246000},"page":"6236-6246","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Selinexor combined with R-CHOP achieved a high response rate in newly diagnosed double\/triple-hit lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5976-7562","authenticated-orcid":false,"given":"Cong","family":"Li","sequence":"first","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4592-850X","authenticated-orcid":false,"given":"Xi","family":"Chen","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2721-7280","authenticated-orcid":false,"given":"Jieyu","family":"Xu","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3920-5785","authenticated-orcid":false,"given":"Tao","family":"Lei","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Yu","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuailing","family":"Peng","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0004-2812","authenticated-orcid":false,"given":"Shuiyun","family":"Han","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2026092210522228400_bib1","doi-asserted-by":"crossref","first-page":"1297405","DOI":"10.3389\/fonc.2024.1297405","article-title":"The trend of lymphoma incidence in China from 2005 to 2017 and lymphoma incidence trend prediction from 2018 to 2035: a log-linear regression and Bayesian age-period-cohort analysis","volume":"14","author":"Lin","year":"2024","journal-title":"Front Oncol"},{"issue":"9","key":"2026092210522228400_bib2","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/s41379-018-0067-x","article-title":"MYC\/BCL2\/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC\/BCL2 and MYC\/BCL6 double hit lymphomas","volume":"31","author":"Huang","year":"2018","journal-title":"Mod Pathol"},{"issue":"7","key":"2026092210522228400_bib3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"20","key":"2026092210522228400_bib4","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2026092210522228400_bib5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2026092210522228400_bib6","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1365-2559.2012.04351.x","article-title":"Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?","volume":"61","author":"Mationg-Kalaw","year":"2012","journal-title":"Histopathology"},{"issue":"6","key":"2026092210522228400_bib7","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","volume":"166","author":"Oki","year":"2014","journal-title":"Br J Haematol"},{"issue":"15","key":"2026092210522228400_bib8","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2026092210522228400_bib9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/PAS.0b013e31826cebad","article-title":"Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas","volume":"37","author":"Pillai","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"2026092210522228400_bib10","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.3390\/cancers12113305","article-title":"Immunophenotypic landscape and prognosis of diffuse large B-cell lymphoma with MYC\/BCL2 double expression: an analysis of a prospectively immunoprofiled cohort","volume":"12","author":"Han","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2026092210522228400_bib11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/PAS.0b013e3181cd3aeb","article-title":"B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma","volume":"34","author":"Snuderl","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"25","key":"2026092210522228400_bib12","doi-asserted-by":"crossref","first-page":"38122","DOI":"10.18632\/oncotarget.9473","article-title":"Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC\/BCL2 double hit lymphoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"35","key":"2026092210522228400_bib13","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1200\/JCO.19.00743","article-title":"Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium","volume":"37","author":"Rosenwald","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026092210522228400_bib14","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/leu.2008.344","article-title":"Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC translocations","volume":"23","author":"Niitsu","year":"2009","journal-title":"Leukemia"},{"issue":"11","key":"2026092210522228400_bib15","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"20","key":"2026092210522228400_bib16","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1200\/JCO.2017.72.2157","article-title":"Outcomes of patients with double-hit lymphoma who achieve first complete remission","volume":"35","author":"Landsburg","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026092210522228400_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-020-00903-4","article-title":"XPO1-dependent nuclear export as a target for cancer therapy","volume":"13","author":"Azizian","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2026092210522228400_bib18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-014-0085-1","article-title":"Nucleo-cytoplasmic transport as a therapeutic target of cancer","volume":"7","author":"Gravina","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2026092210522228400_bib19","first-page":"5547","article-title":"Expression of exportin-1 in diffuse large B-cell lymphoma: immunohistochemistry and TCGA analyses","volume":"11","author":"Luo","year":"2018","journal-title":"Int J Clin Exp Pathol"},{"issue":"7","key":"2026092210522228400_bib20","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"issue":"48","key":"2026092210522228400_bib21","doi-asserted-by":"crossref","first-page":"78883","DOI":"10.18632\/oncotarget.12428","article-title":"Selinexor, a selective inhibitor of nuclear export (SINE) compound, acts through NF-\u03baB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death","volume":"7","author":"Kashyap","year":"2016","journal-title":"Oncotarget"},{"issue":"24","key":"2026092210522228400_bib22","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2026092210522228400_bib23","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-20-4929","article-title":"Selinexor in combination with R-CHOP for frontline treatment of non-Hodgkin lymphoma: results of a phase I study","volume":"27","author":"Seymour","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2026092210522228400_bib24","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"27","key":"2026092210522228400_bib25","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026092210522228400_bib26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41408-023-00827-5","article-title":"A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classifications","volume":"13","author":"El-Sharkawi","year":"2023","journal-title":"Blood Cancer J"},{"issue":"4","key":"2026092210522228400_bib27","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/cncr.29781","article-title":"Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma","volume":"122","author":"Landsburg","year":"2016","journal-title":"Cancer"},{"issue":"19","key":"2026092210522228400_bib28","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1182\/blood.2024025681","article-title":"Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis","volume":"144","author":"Abro","year":"2024","journal-title":"Blood"},{"issue":"12","key":"2026092210522228400_bib29","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.3324\/haematol.2019.238162","article-title":"Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial","volume":"105","author":"Chamuleau","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"2026092210522228400_bib30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"2026092210522228400_bib31","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","article-title":"Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial","volume":"20","author":"Davies","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"2026092210522228400_bib32","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol"},{"issue":"7","key":"2026092210522228400_bib33","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/bloodadvances.2023011369","article-title":"A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen","volume":"8","author":"Karmali","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"2026092210522228400_bib34","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/cncr.31877","article-title":"Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2","volume":"125","author":"Godfrey","year":"2019","journal-title":"Cancer"},{"issue":"11","key":"2026092210522228400_bib35","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.3324\/haematol.2018.190157","article-title":"Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements is not associated with MYC\/IG gene rearrangements","volume":"103","author":"McPhail","year":"2018","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2026092210522228400_bib36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood-2021-151266","article-title":"Randomized phase II\/III study of DA-EPOCH-R +\/- venetoclax in previously untreated double hit lymphoma: initial results from alliance A051701","volume":"138","author":"Abramson","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2026092210522228400_bib37","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.2024025725","article-title":"CNS relapse in high-grade B-cell lymphoma with MYC and BCL2 rearrangements and dark-zone signature\u2013expressing DLBCL","volume":"145","author":"Alduaij","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026092210522228400_bib38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13045-022-01249-9","article-title":"Altered pathways and targeted therapy in double hit lymphoma","volume":"15","author":"Zhuang","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2026092210522228400_bib39","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"22","key":"2026092210522228400_bib40","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1158\/0008-5472.CAN-10-2460","article-title":"Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis","volume":"70","author":"Cheung","year":"2010","journal-title":"Cancer Res"},{"issue":"4","key":"2026092210522228400_bib41","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/jha2.315","article-title":"Mutation profiles of diffuse large B-cell lymphoma transformation of splenic B-cell lymphoma\/leukemia, unclassifiable on whole-exome sequencing","volume":"2","author":"Kurosawa","year":"2021","journal-title":"EJHaem"},{"issue":"2","key":"2026092210522228400_bib42","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1158\/1078-0432.CCR-20-2558","article-title":"Mutational landscape and tumor burden assessed by cell-free DNA in diffuse large B-cell lymphoma in a population-based study","volume":"27","author":"Rivas-Delgado","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026092210522228400_bib43","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12916-022-02562-3","article-title":"Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy","volume":"20","author":"Li","year":"2022","journal-title":"BMC Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6236\/2588303\/blooda_adv-2025-018580-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6236\/2588303\/blooda_adv-2025-018580-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:52:31Z","timestamp":1790088751000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/18\/6236\/569788\/Selinexor-combined-with-R-CHOP-achieved-a-high"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":43,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018580","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,22]]},"published":{"date-parts":[[2026,9,11]]}}}